Catalog No.S2466 Synonyms: NSC-12169
Molecular Weight(MW): 288.39
Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
Purity & Quality Control
Choose Selective Estrogen/progestogen Receptor Inhibitors
|Description||Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.|
MTT assays using G-1 shows that, in SkBr3 cells, the proliferative effect induced by 100 nM G-1 is abolished in the presence of 1 μM estriol which acts as an antagonist of GPR30-dependent pathway.  A cell-free transcription assay demonstrates that the antiestrogenic activity exhibited by estriol is because of interferring with estradiol-induced positive cooperative binding and receptor dimerization, binding of hER complexes to ERE, as well as reducing estradiol-dependent transcription in a dose-dependent manner.  A recent study shows that estrogen (estrone, estradiol, and estriol) inhibits Alzheimer's disease-associated low-order Aβ oligomer formation, and among them, estriol shows the strongest in vitro activity. 
|In vivo||In mPTEN+/- mice, estriol treatments resulted in a 187.54% gain in the relative ratio of uterine wet weight to body weight; estriol also increases the ratio to 176.88% in wild-type mice.  Estriol treatment (20 mg/kg ip), in vivo, sensitizes Kupffer cells to LPS via mechanisms dependent on an increase in CD14 by elevated portal blood endotoxin caused by increased gut permeability in rats; while one-half of the rats given estriol intraperitoneally 24 hours before an injection of a sublethal dose of LPS (5 mg/kg) died within 24 hours. |
-  Lappano R, et al. Mol Cell Endocrinol. 2010, 320(1-2), 162-170.
-  Melamed M, et al. Endocrinol. 1997, 11(12), 1868-1878.
-  Morinaga A, et al. Exp Neurol. 2011, 228(2), 298-302.
|In vitro||DMSO||57 mg/mL (197.64 mM)|
|Ethanol||10 mg/mL (34.67 mM)|
|In vivo||Add solvents to the product individually and in order:
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03032848||Completed||Vaginitis Atropic|Pelvic Organ Prolapse|Endometrial Hyperplasia||Universidade Federal do Paraná||November 26, 2013||Phase 4|
|NCT03044652||Recruiting||Vulvovaginal Atrophy||Dr. August Wolff GmbH & Co. KG Arzneimittel|proDERM Institut für Angewandte Dermatologische Forschung GmbH|Bremer Pharmacovigilance Service GmbH|GCP-Service International Ltd. & Co. KG||November 2016||Phase 4|
|NCT02906111||Not yet recruiting||Genital Prolapse||Salvatore Caruso|Policlinico Universitario, Catania||November 2016||Phase 4|
|NCT02967510||Recruiting||Vaginal Atrophy||ITF Research Pharma, S.L.U.||October 2016||Phase 2|
|NCT02892214||Not yet recruiting||Localized Provoked Vulvodynia||Meir Medical Center||October 2016||--|
|NCT02733731||Recruiting||Atrophic Vaginitis||First Affiliated Hospital, Sun Yat-Sen University||February 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.